Back to Search
Start Over
Enhancing the treatment landscape: PET-guided BrECADD for advanced-stage, classical Hodgkin lymphoma.
- Source :
-
Lancet (London, England) [Lancet] 2024 Jul 27; Vol. 404 (10450), pp. 312-313. - Publication Year :
- 2024
-
Abstract
- Competing Interests: I report honorarium for being on a scientific or educational advisory board for Genentech, Novartis, Incyte, Daiichi Sankyo, and Pfizer; being a speaker at Research to Practice; honorarium for being on a data and safety monitoring board for Novartis and Pharmacyclics; being on a board of directors for the American Society of Hematology Research Council; and being a member and Chair-Elect for the Lymphoma Research Foundation scientific advisory board.
- Subjects :
- Humans
Brentuximab Vedotin therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Neoplasm Staging
Immunoconjugates therapeutic use
Immunoconjugates administration & dosage
Hodgkin Disease drug therapy
Hodgkin Disease diagnostic imaging
Positron-Emission Tomography
Subjects
Details
- Language :
- English
- ISSN :
- 1474-547X
- Volume :
- 404
- Issue :
- 10450
- Database :
- MEDLINE
- Journal :
- Lancet (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 39067891
- Full Text :
- https://doi.org/10.1016/S0140-6736(24)01404-1